Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $75 price target on Ultragenyx, saying the company has posted a “very strong” operational print in Q4 with “signals of continued momentum for lead drug Crysvita well into 2019.” The analyst is also positive on the company’s expected global regulatory filings for UX007 as well as significant data from the gene therapy asset base, stating that the catalysts on Ultragenyx are “a’plenty” going into its April analyst day and its potential first look at pre-clinical data for DTX701 in Wilson Disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.